Posted by Michael Wonder on 28 Jun 2024
AbbVie receives positive CHMP opinion for epcoritamab (Tepkinly) for the treatment of adults with relapsed/refractory follicular lymphoma
28 June 2024 - Positive CHMP opinion based on results from the Phase 1/2 EPCORE NHL-1 study.
AbbVie today announced that the EMA's CHMP has adopted a positive opinion recommending the conditional marketing authorization of epcoritamab (Tepkinly), the first and only T-cell engaging bispecific antibody administered subcutaneously (under the skin), as a monotherapy for the treatment of adult patients with relapsed or refractory follicular lymphoma after two or more prior therapies.
